8-K: Cognition Therapeutics Advances Clinical Programs

Cognition Therapeutics reports Q2 2025 financial results and significant progress across its Alzheimer's, DLB, and dry AMD clinical programs.

Summary

• Reported financial results for the second quarter ended June 30, 2025, showing a net loss of $6.7 million, an improvement from $7.0 million in Q2 2024.
• Cash, cash equivalents, and restricted cash equivalents were approximately $11.6 million as of June 30, 2025, with $41.9 million in remaining obligated grant funds from the National Institute of Aging.
• The company estimates sufficient cash to fund operations and capital expenditures into the second quarter of 2026.
• Conducted a productive end-of-Phase 2 (EOP2) meeting with the FDA for zervimesine (CT1812) in Alzheimer's disease.
• Surpassed 50% enrollment in the Phase 2 START study of zervimesine in early Alzheimer's disease.
• Initiated an expanded access program (EAP) for people with dementia with Lewy bodies (DLB), supported by a philanthropic donation.
• Reported positive topline results from a Phase 2 dry AMD study, showing a 28.6% reduction of geographic atrophy (GA) lesion growth at 18 months with zervimesine compared to placebo.
• Applied to the FDA for breakthrough designation for zervimesine in DLB.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical trial results, particularly in dry AMD, and significant progress in regulatory interactions for Alzheimer's and DLB. Financials show an improved net loss, though cash reserves have decreased, necessitating future funding strategies. Overall, the clinical advancements and regulatory momentum are highly positive for a clinical-stage biotech.

Positives

• Net loss decreased to $6.7 million in Q2 2025 from $7.0 million in Q2 2024, indicating improved financial performance.
• Net loss per share improved to $(0.11) in Q2 2025 from $(0.18) in Q2 2024.
• Research and development expenses slightly decreased to $11.5 million in Q2 2025 from $11.6 million in Q2 2024.
• General and administrative expenses decreased to $2.5 million in Q2 2025 from $3.1 million in Q2 2024, primarily due to reduced stock-based compensation.
• Productive EOP2 meeting with FDA for zervimesine in Alzheimer's disease, indicating progress towards registrational plans.
• Over 50% enrollment achieved in the Phase 2 START study for early Alzheimer's disease, supported by an $81 million NIA grant.
• Positive topline results from the Phase 2 dry AMD study, demonstrating a 28.6% reduction in geographic atrophy lesion growth at 18 months.
• Initiation of an expanded access program for DLB patients, supported by philanthropic funding, addresses an unmet medical need.
• Application for FDA breakthrough designation for zervimesine in DLB highlights the potential significance of the therapy.

Negatives

• Cash, cash equivalents, and restricted cash equivalents decreased significantly to $11.6 million as of June 30, 2025, from $25.0 million as of December 31, 2024.
• Weighted-average common shares outstanding increased substantially to 63,690,945 in Q2 2025 from 40,062,954 in Q2 2024, indicating significant dilution.

Risks

• Competition from other companies developing treatments for neurodegenerative disorders.
• Ability to secure new and retain existing grant funding, which is crucial for clinical development.
• Challenges in managing growth, maintaining supplier relationships, and retaining key management and employees.
• Uncertainties inherent in preliminary data, pre-clinical studies, and earlier-stage clinical trials being predictive of results in later-stage trials.
• The timing, scope, and likelihood of regulatory filings and approvals for product candidates.
• Changes in applicable laws or regulations that could impact development or commercialization.
• Adverse effects from economic, business, or competitive factors, including ongoing economic uncertainty.
• Ability to defend intellectual property rights.
• Impacts of global political changes, economic conditions, supply chain disruptions, and labor force issues.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market.

Future Outlook

The company anticipates receiving the FDA's minutes from its end-of-Phase 2 meeting regarding registrational plans for zervimesine in Alzheimer's disease later this month, expecting confirmation of the Agency's expectations for a clinical program. Additionally, a decision from the FDA on breakthrough designation for zervimesine in DLB is expected in the third quarter of 2025. These milestones are expected to be valuable for potential partners as the company evaluates options to support zervimesine's development.

Management Comments

• "The second quarter of 2025 has been very productive, with milestones from each of our clinical programs."
• "These accomplishments highlight the potential for zervimesine to slow the progression of age-related degenerative diseases such as Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD)."
• "The clinical findings from each program have been supplemented by the publication of proteomic analyses and in vitro studies that support the mechanism of action of zervimesine in these patient populations."
• "Later this month we anticipate receiving the FDAs minutes from our end-of-Phase 2 meeting regarding registrational plans for zervimesine in Alzheimers disease. We expect these will confirm our understanding of the Agency's expectations for a clinical program in Alzheimers disease."
• "In addition, we expect FDA will have a decision on breakthrough designation for zervimesine in DLB in the third quarter 2025. We expect these milestones will be valuable to potential partners as we continue to evaluate our options to support development of zervimesine."

Industry Context

Cognition Therapeutics operates in the highly competitive and high-risk, high-reward biopharmaceutical sector, specifically targeting neurodegenerative disorders like Alzheimer's, DLB, and dry AMD. These diseases represent significant unmet medical needs with large patient populations. The company's focus on the sigma-2 receptor mechanism of action for zervimesine offers a functionally distinct approach compared to many other therapies in development, which often target amyloid or tau pathways. Positive Phase 2 results and ongoing FDA interactions are critical for clinical-stage biotechs to attract partnerships and secure future funding, positioning Cognition as a notable player in this challenging therapeutic area.

Comparison to Industry Standards

• The 28.6% reduction in geographic atrophy (GA) lesion growth at 18 months in the dry AMD study is a significant positive outcome, especially for an oral, once-daily treatment. This result compares favorably to existing or late-stage therapies for GA, which often involve intravitreal injections and have shown varying degrees of efficacy (e.g., Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) have demonstrated reductions in GA lesion growth, typically in the range of 17-26% over 12-24 months in their pivotal trials, but require injections). Zervimesine's oral administration could offer a significant patient convenience advantage.
• Progress in Alzheimer's disease with productive FDA EOP2 meetings and over 50% enrollment in the Phase 2 START study, supported by an $81 million NIA grant, indicates strong institutional validation and aligns with the industry's push for diverse therapeutic approaches beyond amyloid-beta targeting, especially for early-stage disease.
• The application for FDA breakthrough designation for zervimesine in DLB suggests the company believes the data from the Phase 2 SHIMMER study is compelling enough to warrant expedited review, a status granted to therapies that address serious conditions and demonstrate substantial improvement over available therapies. This is a high bar and, if granted, would place zervimesine among a select group of promising DLB treatments.

Stakeholder Impact

• **Shareholders**: Positive clinical trial results and regulatory progress could lead to increased share value, but significant share dilution has occurred, and future funding needs remain.
• **Patients**: Progress in clinical programs for Alzheimer's, DLB, and dry AMD offers hope for new, effective treatment options, particularly with the initiation of an expanded access program for DLB.
• **Employees**: Continued clinical progress and potential partnerships could ensure job security and growth opportunities.
• **Creditors/Grantors**: The company's ability to fund operations into Q2 2026, supported by significant NIA grant funds, provides a degree of financial stability.

Next Steps

• Receive FDA's minutes from the end-of-Phase 2 meeting regarding registrational plans for zervimesine in Alzheimer's disease later in August 2025.
• Await FDA decision on breakthrough designation for zervimesine in DLB in the third quarter of 2025.
• Continue enrollment in the Phase 2 START study of zervimesine in early Alzheimer's disease.
• Continue to evaluate options to support the development of zervimesine, potentially including partnerships.
• Submit comprehensive manuscript describing proposed mechanism of action of zervimesine in the treatment of dry AMD / GA to a peer-reviewed journal.

Key Dates

Recommendation

The filing indicates substantial clinical progress across multiple high-impact neurodegenerative diseases, including positive Phase 2 dry AMD results and significant advancements in Alzheimer's and DLB programs with active FDA engagement. The improved net loss, while cash reserves have decreased, is offset by a clear path for future funding through grants and potential partnerships. The distinct mechanism of action of zervimesine and the pursuit of breakthrough designation for DLB suggest high therapeutic potential. For a clinical-stage biotech, these milestones are critical value drivers, making the stock an attractive 'buy' for investors with a long-term horizon and appetite for biotech risk.

Keywords

Alzheimer's disease, Dementia with Lewy bodies, Dry age-related macular degeneration, Zervimesine, CT1812, Neurodegenerative disorders, Clinical trials, Biopharmaceutical, FDA breakthrough designation, Sigma-2 receptor